|
| 37619245 | A Retrospective Genomic Landscape of 661 Young Adult Glioblastomas Diagnosed Using 2016 WHO Guidelines for Central Nervous System Tumors. | Oncologist | 2024 |
| 37164276 | RNA Sequencing Identifies Novel NRG1 Fusions in Solid Tumors that Lack Co-Occurring Oncogenic Drivers. | | 2023 |
| 35771716 | Method of Tissue Acquisition Affects Success of Comprehensive Genomic Profiling in Lung Cancer. | Arch Pathol Lab Med | 2023 |
| 36284031 | Diversity and transparency in gynecologic oncology clinical trials. | Cancer Causes and Control | 2023 |
| 36342081 | Genomic Profiling Reveals Differences in Primary Central Nervous System Lymphoma and Large B-Cell Lymphoma, With Subtyping Suggesting Sensitivity to BTK Inhibition. | Oncologist | 2023 |
| 35747993 | Genomic landscape of non-small-cell lung cancer with methylthioadenosine phosphorylase (MTAP) deficiency. | Cancer Med | 2023 |
| 36443178 | Novel synthetic lethality drug target in urothelial bladder cancer based on MTAP genomic loss. | Urol Oncol | 2023 |
| 37586297 | Clinical characterization of the mutational landscape of 24,639 real-world samples from patients with myeloid malignancies. | | 2023 |
| 37722087 | Inaugural Results of the Individualized Screening Trial of Innovative Glioblastoma Therapy: A Phase II Platform Trial for Newly Diagnosed Glioblastoma Using Bayesian Adaptive Randomization. | J Clin Oncol | 2023 |
| 36780194 | ALK Amplification and Rearrangements Are Recurrent Targetable Events in Congenital and Adult Glioblastoma. | Clin Cancer Res | 2023 |
| 37068734 | Validation of the Labcorp Plasma Focus Test to Facilitate Precision Oncology Through Cell-Free DNA Genomic Profiling of Solid Tumors. | | 2023 |
| 37172552 | Antibody-drug conjugates, immune-checkpoint inhibitors, and their combination in advanced non-small cell lung cancer. | | 2023 |
| 36862145 | POU2AF3-rearranged sarcomas: A novel tumor defined by fusions of EWSR1 or FUS to a gene formerly designated COLCA2. | Genes Chromosomes Cancer | 2023 |
| 37427115 | Mechanisms of immune modulation in the tumor microenvironment and implications for targeted therapy. | | 2023 |
| 35156038 | Multivariate analysis of associations between clinical sequencing and outcome in glioblastoma. | Neurooncol Adv | 2022 |
| 36028784 | PD-L1 protein expression in relation to recurrence score values in early-stage ERâ¿¿+â¿¿breast cancer. | Breast Cancer Res Treat | 2022 |
| 35949590 | mutant small cell glioblastoma in a patient with Gorlin syndrome: A case report. | Oncology Letters | 2022 |
| 35878398 | Clinical Laboratory Testing Practices in Diffuse Gliomas Prior to Publication of 2021 World Health Organization Classification of Central Nervous System Tumors. | Arch Pathol Lab Med | 2022 |
| 35749302 | Comprehensive Genomic Profiling of 274 Thymic Epithelial Tumors Unveils Oncogenic Pathways and Predictive Biomarkers. | Oncologist | 2022 |
| 35552752 | Variable Genomic Landscapes of Advanced Melanomas with Heavy Pigmentation. | Oncologist | 2022 |
| 35598205 | Clinicopathologic and Genomic Landscape of Non-Small Cell Lung Cancer Brain Metastases. | Oncologist | 2022 |
| 35034043 | HPV51-associated Leiomyosarcoma: A Novel Class of TP53/RB1-Wildtype Tumor With Predilection for the Female Lower Reproductive Tract. | Am J Surg Pathol | 2022 |
| 34998597 | Molecular analysis of endometrial serous carcinoma reveals distinct clinicopathologic and genomic subgroups. | Gynecol Oncol | 2022 |
| 34379803 | Contrasting genomic profiles from metastatic sites, primary tumors, and liquid biopsies of advanced prostate cancer. | Cancer | 2021 |
| 35602225 | Pan-cancer analysis of the effect of biopsy site on tumor mutational burden observations. | Commun Med (Lond) | 2021 |
| 35601813 | Clinical Experience using Osimertinib in Patients with Recurrent Malignant Gliomas Containing Alterations. | | 2021 |
| 34130989 | Pan-cancer analysis of <i>CD274</i> (PD-L1) mutations in 314,631 patient samples and subset correlation with PD-L1 protein expression. | J Immunother Cancer | 2021 |
| 33637877 | Clinicopathologic and genomic characterization of PD-L1-positive uterine cervical carcinoma. | Mod Pathol | 2021 |
| 34169283 | Erratum to: FoundationOne CDx testing accurately determines whole arm 1p19q codeletion status in gliomas. | Neurooncol Adv | 2021 |
| 33904632 | Histiocytic and Dendritic Cell Sarcomas of Hematopoietic Origin Share Targetable Genomic Alterations Distinct from Follicular Dendritic Cell Sarcoma. | Oncologist | 2021 |
| 33687775 | Clinicopathologic and Genomic Characterization of PD-L1 Positive Urothelial Carcinomas. | Oncologist | 2021 |
| 34282751 | Clinically Advanced Pheochromocytomas and Paragangliomas: A Comprehensive Genomic Profiling Study. | Cancers (Basel) | 2021 |
| 34215504 | Comprehensive genomic profiling of histologic subtypes of urethral carcinomas. | Urol Oncol | 2021 |
| 34105517 | JAK2 Rearrangements Are a Recurrent Alteration in CD30+ Systemic T-Cell Lymphomas With Anaplastic Morphology. | American Journal of Surgical Pathology | 2021 |
| 34105210 | Clinicopathologic and Genomic Landscape of Breast Carcinoma Brain Metastases. | Oncologist | 2021 |
| 33778493 | FoundationOne CDx testing accurately determines whole arm 1p19q codeletion status in gliomas. | Neurooncol Adv | 2021 |
| 33833050 | Comparison of programmed death-ligand 1 protein expression between primary and metastatic lesions in patients with lung cancer. | J Immunother Cancer | 2021 |
| 33775530 | Comprehensive genomic profiling of metastatic collecting duct carcinoma, renal medullary carcinoma, and clear cell renal cell carcinoma. | Urol Oncol | 2021 |
| 33772213 | IDH-mutant gliomas with additional class-defining molecular events. | Mod Pathol | 2021 |
| 34257540 | Landscape of Biomarkers in Non-small Cell Lung Cancer Using Comprehensive Genomic Profiling and PD-L1 Immunohistochemistry. | Pathol Oncol Res | 2021 |
| 34333275 | Genomic profiling of solid tumors harboring BRD4-NUT and response to immune checkpoint inhibitors. | Transl Oncol | 2021 |
| 34309133 | Rapid Progression of Metastatic Pancreatic Adenocarcinoma During Platinum-Based Therapy in a Patient Harboring a Pathogenic BRCA2 Germline Variant. | Oncologist | 2021 |
| 34302054 | Clinicopathological and genomic characterization of BCORL1-driven high-grade endometrial stromal sarcomas. | Mod Pathol | 2021 |
| 32884129 | A pan-cancer analysis of PD-L1 immunohistochemistry and gene amplification, tumor mutation burden and microsatellite instability in 48,782 cases. | Mod Pathol | 2021 |
| 33314633 | Predictive Biomarkers for Immune Checkpoint Inhibitors in Metastatic Breast Cancer. | Cancer Med | 2021 |
| 32918774 | Targetable BRAF and RAF1 Alterations in Advanced Pediatric Cancers. | Oncologist | 2021 |
| 33077920 | Recurrent urothelial carcinoma-like FGFR3 genomic alterations in malignant Brenner tumors of the ovary. | Mod Pathol | 2021 |
| 32892208 | CYLD mutation characterizes a subset of HPV-positive head and neck squamous cell carcinomas with distinctive genomics and frequent cylindroma-like histologic features. | Mod Pathol | 2021 |
| 34626187 | Circulating Cell-Free DNA Yield and Circulating-Tumor DNA Quantity from Liquid Biopsies of 12â¿¿139 Cancer Patients. | Clin Chem | 2021 |
| 30025711 | Genomic Characterization of Testicular Germ Cell Tumors Relapsing After Chemotherapy. | Eur Urol Focus | 2020 |